Companies / GTG

GENETIC TECHNOLOGIES LIMITED

ASX:GTGPharmaceuticals, Biotechnology & Life Sciences
1.34B shares on issueASX (delayed) · as of 28 July 2026$0.039price · delayed—market cap · indicative
B
Dilution grade

Share count grew 800% in 24 months; 2 cash raises in 24 months

Cash runway272.7 quarters of funding
Share-count growth (24m)800.1%
Raise cadence (24m)2 cash raises
Options & rights overhang2.6% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

GENETIC TECHNOLOGIES LIMITED's ordinary share count grew 800.1% between July 2024 and May 2025, to 1.31B shares. The company recorded two capital raises in the 24-month window, with total disclosed proceeds of A$268K and the most recent A$268K in May 2025. Options and rights on issue could convert into 35M new shares, equal to 2.6% of the current share count, with 0% in the money at present. At the September 2025 quarter the company reported A$273K in available cash, representing 272.7 quarters of cover at its disclosed rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
2.6%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
272.7 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.34B per ASX (delayed) (28 July 2026).
0.40B0.74B1.09BDec 24Sept 25July 26Cash raise · 14 May 2025Cash raise · 14 May 2025

Cash runway

272.7 qtrs
More than four quarters of funding at the recent spend rate.
$273k available cash at quarter ended 30 Sept 2025 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 Sept 2025.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
6 Feb 20263H · cancellationGTG : ORDINARY FULLY PAID1.34BAppendix 3H
23 May 20253H · cancellationGTG : ORDINARY FULLY PAID1.34BAppendix 3H
23 May 20253H · cancellationGTG : ORDINARY FULLY PAID1.34BAppendix 3H
21 May 20252A · quoted issueGTG : ORDINARY FULLY PAID1.31BAppendix 2A
21 May 20252A · quoted issueGTG : ORDINARY FULLY PAID171.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 0 in the last 12 months

$268k
Capital raise
14 May 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

2.6%
Total overhang · of current shares
0.0%
In the money · at current price
35.0M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

22 June 2026Termination of ADR Facility
30 Mar 2026$PQuarterly Activities/Appendix 4C Cash Flow Report Sept 2025
30 Mar 2026$PQuarterly Activities/Appendix 4C Cash Flow Report June 2025
30 Mar 2026$PQuarterly Activities/Appendix 4C Cash Flow Report March 2025
27 Mar 2026Initial Director's Interest Notice - Campbell Welch
27 Mar 2026Initial Director's Interest Notice - Jeffrey Le Compte
27 Mar 2026Final Director's Interest Notice - William Musgrave
27 Mar 2026Final Director's Interest Notice - Steven Nicols
24 Mar 2026Update on Board Changes
24 Mar 2026$PUpdate on Proposed Acquisition Strategy
6 Mar 2026Chief Financial Officer Resignation
6 Feb 2026Notification of cessation of securities - GTG
19 Dec 2025Final Director's Interest Notice - A Hartman
19 Dec 2025Initial Director's Interest Notice - S Nicols
19 Dec 2025Director Resignation and Appointment
2 Dec 2025Resignation of Joint Company Secretary
20 Aug 2025$PQuarterly Activities/Appendix 4C Cash Flow Report
20 Aug 2025$PFY25 Appendix 4D and Half Year Accounts
30 June 2025Change of Auditor
6 June 2025$PBinding Term Sheets Executed

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.